Current research indicates that CHOP is largely consistent with the product insert for precursor T-lymphoblastic lymphoma/leukAEsmia recurrent, T-cell lymphoma recurrent, metastases to reproductive organ, therapy responder, and chronic lymphocytic leukAEsmia recurrent. This evidence concerns the gene DDIT3 and T-cell non-Hodgkin lymphoma.